sarepta therapeutics fda

News

Sarepta Will Resume Gene Therapy Shipments

FDA’s Prasad Exits Following Political Backlash Over Sarepta

Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his handling of Sarepta Therapeutics Inc.’s gene therapy. “Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,

Fierce Pharma · 5h

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy

Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation and Research, overseeing vaccines and cell and gene therapies. | Controversies,

The Associated Press on MSN · 1d

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

23hon MSN

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

21h

Sarepta soars after FDA says some patients can get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...

MedPage Today on MSN5h

FDA's Top Vaccine Chief Resigns

After just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics ...

US FDA's top vaccine official Vinay Prasad leaves agency after 3 months

The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

1don MSN

Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

2hon MSN

FDA chief scientific officer Vinay Prasad resigns

Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...

2don MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results